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Abstract: Without sufficient herd immunity through either vaccination or natural infection, the
coronavirus disease 2019 pandemic is unlikely to be controlled. Waning immunity with the currently approved vaccines suggests the need to evaluate vaccines causing the induction of long-term
responses. Here, we report the immunogenicity and efficacy of our adjuvanted single-dose Rabiesvectored SARS-CoV-2 S1 vaccine, CORAVAX, in hamsters. CORAVAX induces high SARS-CoV-2
S1-specific and virus-neutralizing antibodies (VNAs) that prevent weight loss, viral loads, disease,
lung inflammation, and the cytokine storm in hamsters. We also observed high Rabies VNA titers. In
summary, CORAVAX is a promising dual-antigen vaccine candidate for clinical evaluation against
SARS-CoV-2 and Rabies virus.
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Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) was first reported
in Wuhan, China, in December 2019 and accounts for over 264 million infections and
5.22 million deaths at the time of this report [1]. SARS-CoV-2 infection in humans causes
coronavirus-19 disease (COVID-19), resulting in mild or severe clinical manifestations that
mainly affect the respiratory system.
SARS-CoV-2 is an enveloped virus containing the spike (S) glycoprotein on its surface,
which is required for viral entry into cells [2]. The S protein is the main target for current
vaccine development because antibodies directed against this protein can neutralize the
virus. Fast-tracked research efforts by academic institutions and biotech companies led
to the development and approval of several SARS-CoV-2 S-protein-based vaccines that
induce neutralizing antibodies [2]. Recent studies suggest that neutralizing antibody levels
are highly predictive of immune protection from symptomatic SARS-CoV-2 infection [3].
Whereas the previous SARS-CoV was controlled using social isolation and screening,
control of the spread of SARS-CoV-2 has proven very challenging. Fast-tracked vaccine
development and approval led to vaccine administration by December 2020 and into early
January 2021 in several countries. Despite these efforts, controlling the pandemic has been
difficult due to several factors: (1) high transmissibility, (2) transmission by asymptomatic
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individuals, (3) unequal distribution of vaccines worldwide, (4) emergence of variants with
higher transmissibility, and (5) vaccine hesitancy.
The first mRNA-based COVID-19 vaccines were approved around December 2020
(BNT162b: Pfizer-BioNTech, USA-Germany; mRNA-1273: Moderna, USA). These vaccines
use a lipid-based delivery platform and an almost identical antigen, a prefusion-stabilized
SARS-CoV-2 spike protein-encoding mRNA. The vaccines differ in their proprietary lipid
delivery platform and the amount of antigen used (30 µg for Pfizer and 100 µg for Moderna).
Both vaccines provide exceptionally high protection, preventing about 95% of symptomatic
COVID-19 disease and 100% of severe COVID-19 disease [4,5]. However, the induced
immune responses are not long-lasting, and a booster is required after six months.
Single-dose vaccines have a significant advantage, as they allow for greater vaccination
coverage and better patient compliance. The Johnson & Johnson (J&J, USA) Ad26.COV2.S
vaccine is the only single-dose vaccine that has been evaluated and received FDA approval
in the United States. The J&J vaccine comprises a recombinant, replication-incompetent human adenovirus type 26 (Ad26) vector encoding a full-length, membrane-bound prefusionstabilized S protein. Although phase 3 clinical trial data reported a vaccine efficacy of
66.9% against moderate to severe-critical COVID-19, the vaccine immunity wanes after
two months, requiring a booster dose [6,7] and limiting the utility of this vaccine candidate. Interestingly, a preclinical study with a single intranasal dose of a live-attenuated
parainfluenza virus-vectored SARS-CoV-2 vaccine was protective in hamsters [8]. However,
long-term responses are yet to be determined for this vector.
The high transmissibility of SARS-CoV-2 in the absence of sufficient vaccine coverage
has led to the emergence of several variants. The World Health Organization (WHO) has recently classified two variants of concern, Delta and Omicron. Follow-up studies conducted
during the emergence of the Delta variant have shown waning immunity for all approved
vaccines, including those from Pfizer and Moderna, with the most extreme decline for the
J&J vaccine [9]. Due to the prevalence of the Delta variant, the CDC recommends booster
doses for all three approved vaccines. Scientists have also recommended differential dosing
for infected versus naïve individuals, as a single dose of an mRNA vaccine in previously
infected individuals provided antibody titers similar to two doses in a naïve person [10].
These results indicate the great success of vaccines in preventing COVID-19 but also suggest
that new, cost-effective vaccines inducing long-lasting immunity are crucial.
Our previous studies demonstrated the efficacy of two doses of our inactivated COVID19 vaccine, CORAVAX, in hamsters. CORAVAX is an adjuvanted inactivated vaccine
generated using the SAD-B19 Rabies vaccine strain encoding the S1 subunit of SARS-CoV-2.
This study evaluates the efficacy of a single dose of CORAVAX in a hamster model of
severe disease. A single dose of adjuvanted CORAVAX induced high S1 and RBD IgG
responses along with high virus-neutralizing antibodies against SARS-CoV-2. The singledose vaccination protected vaccinated animals from weight loss and lung inflammation,
reduced lung viral loads, and alleviated the lung cytokine storm.
2. Materials and Methods
2.1. Ethics Statement
The studies were carried out according to the recommendations described in the
Guide for the Care and Use of Laboratory Animals of the National Research Council.
Thomas Jefferson University (TJU) is an AAALAC-accredited institution, and the IACUC
Committee approved all animal work of TJU (protocol number 02173). All efforts were
made to minimize animal suffering, and all procedures involving potential pain were
performed with the appropriate anesthetic or analgesic. The number of hamsters used
was scientifically justified based on statistical analyses of virological and immunological
outcomes. Six-to-eight-week-old golden Syrian female hamsters (Envigo) were anesthetized
with 5% isoflurane before immunization, blood collection, and the SARS-CoV-2 challenge.
Animals were monitored daily for weight loss and signs of disease. Five of the animals in
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each group were euthanized by an overdose of CO2 inhalation on day 3 (day 42), day 7
(day 46), and day 14 (53) p.c. for viral load determination and analysis.
2.2. Viruses
The SARS-CoV-2 strain used in this study is the first U.S. isolate SARS-CoV-2 USA_WA1/
2020 from the Washington State patient identified on 22 January 2020. This virus was
deposited by the Centers for Disease Control and Prevention and obtained through BEI
Resources (Manassas, VA, USA), NIAID, NIH (SARS-Related Coronavirus 2, Isolate USAWA1/2020, NR-52281). Virus stocks were obtained at passage 4 (GenBank: MN985325.1)
and propagated in Vero E6 cells. The stock used in this study is passage 5.
2.3. Cells
Vero (ATCC, CCL81), Vero E6 (ATCC, CRL-1586), BSR (a clone of baby hamster kidney
cells), HEK-293T (ATCC, CRL 3216), and effector cells (murine FcγRIV ADCC Bioassay
Effector Cells, Promega-M1201) were used.
2.4. Vaccine Production and Purification
Recombinant RABV virions were recovered, purified, inactivated, and titered as
described previously [11]. Briefly, X-tremeGENE 9 transfection reagent (Millipore Sigma,
St. Louis, MO, USA; Cat# 6365809001) was used to co-transfect the full-length viral cDNA
clone encoding CORAVAX and plasmids encoding RABV N, P, and L proteins and T7 RNA
polymerase into BSR cells in 6-well plates (RABV). At eight days post-transfection, the
supernatant was collected, filtered through a 0.22 µm membrane filter (Millipore, St. Louis,
MO, USA), and titrated on Vero cells. The presence of recombinant virus was verified by
immunostaining with a monoclonal antibody against the RABV nucleoprotein (FujiRebio,
Malvern, PA, USA; Cat# 800–092) and polyclonal antiserum against the SARS-CoV/CoV-2
S1 domain (Thermo Fisher, Corning, NY, USA; Cat# PA581798). The filtered virus was then
used to inoculate Vero cells seeded in Cellstack Culture Chambers (Thermo Fisher Scientific,
Corning, NY, USA) and propagated in VP-SFM medium (Thermo Fisher Scientific, Corning,
NY, USA) over 18 days. Supernatant collected on day 10 post-infection was filtered through
0.45 µm PES membrane filters (Thermo Fisher Scientific, Corning, NY, USA) and layered
onto 20% sucrose in DPBS. Virions were sedimented by ultracentrifugation in an SW32
rotor for 1.5 h at 25,000 rpm. Viral particles were resuspended in phosphate-buffered saline
(PBS) and inactivated with 50 µL per mg of particles of a 1:100 dilution of β-propiolactone
(BPL, Millipore Sigma, St. Louis, MO, USA; Cat# P5648) in cold water. The absence of
infectious particles was verified by inoculating BSR cells with 10 µg of BPL-inactivated
viruses over three passages.
2.5. Vaccination and SARS-CoV-2 Challenge
Thirty hamsters were housed individually in microisolator cages. Each animal received 10 µg of vaccine or control mixed with 50 µL of SEPIVAC (Seppic, Courbevoie,
France) adjuvant (50:50, by volume) brought up to 100 µL with 1× DPBS. Hamsters were
anesthetized using isoflurane for vaccination, bleeding, and challenge procedures. The
hamsters were bled on days 0 (pre-dosing), 14, and 28. Hamsters were vaccinated once
on day 0 with 50 µL of formulated vaccine or control injected intramuscularly into each
thigh of the hamster (100 µL total dose/animal). On day 39, hamsters were weighed
and then challenged intranasally with 100 µL of 1 × 104 PFU of SARS-CoV-2 Washington
strain dropwise into each nostril. Post-challenge, the hamsters were weighed daily and
assessed for symptoms. On days 3, 7, and 14 post-challenge, five hamsters from each group
were weighed and humanely sacrificed under steady CO2 conditions. Cardiac blood was
collected, and cervical dislocation was performed. The nasal turbinates, lungs, and kidneys
were harvested for determining qPCR viral RNA titers and infectious viral load. One lung
lobe was placed in 4% formaldehyde and placed on ice. The spleen was harvested for RNA
isolation in tubes prefilled with ceramic beads and 1000 µL of TRIzol tubes.
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2.6. Recombinant Proteins for ELISA
Purification of the HA-tagged S1 protein from the supernatant of transfected cells for ELISA:
Sub-confluent T175 flasks of 293T cells (human embryonic kidney cell line, ATCC) were
transfected with a pDisplay vector encoding amino acids 16 to 682 of SARS-CoV-2 S (S1)
fused to a C-terminal hemagglutinin (HA) peptide using X-tremeGENE 9 reagent (Millipore
Sigma, St. Louis, MO, USA; Cat# 6365809001). The supernatant was collected six days
post-transfection, filtered through 0.22 um PES membrane filters (Thermo Fisher, Corning,
NY, USA), and then loaded onto anti-HA agarose (Thermo Fisher Scientific, Corning, NY,
USA, Cat# 26182) column equilibrated in PBS. After washing with ten bed volumes of
PBS, the column was loaded with two column volumes of HA peptide at a 400 µg/mL
concentration in PBS and incubated overnight at 4 ◦ C. The following day, the protein was
eluted with two column volumes of HA peptide followed by two column volumes of
PBS. Fractions were collected and analyzed by Western blotting with polyclonal antiserum
against the S1 domain (Thermo Fisher, Corning, NY, USA; Cat# PA581798). Peak fractions
were then pooled and dialyzed against PBS in 10,000 molecular weight cutoff (MWCO)
dialysis cassettes (Thermo Fisher Scientific, Corning, NY, USA; Cat# 66380) to remove
excess HA peptides. After dialysis, the protein was quantitated by UV spectrophotometry
and frozen in small aliquots at −80 ◦ C.
Purification of the RBD-His protein for ELISA: The SARS-CoV-2 RBD-His-tagged plasmid
was purchased from Bei Resources (Manassas, VA, USA; NR-52309). Sub-confluent T175
flasks of 293T cells (human embryonic kidney cell line) were transfected with the RBD-Histagged plasmid using X-tremeGENE 9 reagent (Millipore Sigma, St. Louis, MO, USA; Cat#
6365809001). The supernatant was collected six days post-transfection and filtered through
0.22 µm PES membrane filters (Thermo Fisher Scientific, Corning, NY, USA). The 5 mL
HisTALON cartridge (Clontech Laboratories, San Jose, CA, USA; Cat# 635683) column
was equilibrated with ten column volumes of Equilibration Buffer (HisTALON Buffer Set,
Clontech Laboratories, San Jose, CA, USA; Cat# 635651). The filtered supernatant was
loaded onto the HisTALON cartridge (Clontech Laboratories, San Jose, CA, USA; Cat#
635683) column at a speed of 1 mL/min. After washing with 10 column volumes of Wash
Buffer (prepared by mixing 6.6 parts of Elution Buffer with 93.4 parts of Equilibration
Buffer of the HisTALON Buffer Set), the sample was eluted (at a flow rate of ~1 mL/min)
with approximately 8 column volumes of Elution Buffer, collecting 1 mL fractions. The
sample protein concentration was assessed by measuring the absorbance of the eluted
fractions at 280 nm (Nanodrop, Thermo Fisher Scientific, Corning, NY, USA). Eluted fractions were analyzed by Western blotting with a mouse monoclonal RBD-specific antibody
(InvivoGen, San Diego, CA, USA; Cat# srbdmab10). Peak fractions were then pooled and
dialyzed against PBS in 10,000 molecular weight cutoff (MWCO) dialysis cassettes (Thermo
Fisher Scientific, Corning, NY, USA). After dialysis, the protein was quantitated by UV
spectrophotometry and frozen in small aliquots at −80 ◦ C.
2.7. Enzyme-Linked Immunosorbent Assay
To determine antibody responses to the S protein of SARS-CoV-2, an indirect ELISA
was developed utilizing purified S1 or receptor-binding domain (RBD) protein. The production of the recombinant proteins is described above. An indirect ELISA measured
humoral responses to SARS-CoV-2 S1 and RBD proteins. We tested individual hamster
sera by enzyme-linked immunosorbent assay (ELISA) for the presence of IgG specific to
SARS-CoV-2 S1 or RBD. To test for anti-SARS-CoV-2 S1 humoral responses, we produced
soluble S1 or RBD as described above. The two recombinant proteins were resuspended in
coating buffer (50 mM Na2 CO3 [pH 9.6]) at a concentration of 0.5 µg/mL of S1 or 1 µg/mL
of RBD, and then they were plated in 96-well ELISA MaxiSorp plates (Thermo Fisher
Scientific, Corning, NY, USA) at 100 µL in each well. After overnight incubation at 4 ◦ C,
plates were washed three times with 1× PBST (0.05% Tween 20 in 1× PBS), followed by
the addition of 250 µL of blocking buffer (5% dry milk powder in 1× PBST) and incubation
at room temperature for 1.5 h. The plates were then washed three times with PBST and
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incubated overnight at 4 ◦ C with serial dilutions of sera (three-fold dilutions in triplicate)
in 1× PBST containing 0.5% BSA. Plates were washed three times the next day, followed by
the addition of HRP-conjugated goat anti-Syrian hamster IgG secondary antibody (Jackson
Immunoresearch, West Grove, PA, USA; Cat# 107-035-142, 1:8000 in PBST) or mouse antihamster-IgG2/3-HRP (Southern Biotech, Birmingham, AL, USA; Cat# 1935–05, 1:8000 in
PBST) or mouse anti-hamster-IgG1-HRP (Southern Biotech, Cat# 1940–05, 1:8000 in PBST)
for 2 h at RT. After the incubation, plates were washed three times with PBST, and 100 µL
of o-phenylenediamine dihydrochloride (OPD) substrate (Thermo Scientific, Corning, NY,
USA; Cat#34006 and 34062) was added to each well. The reaction was stopped by adding
50 µL of 3 M H2 SO4 per well. Optical density was determined at 490 nm (OD490) and
630 nm (OD630) using an ELX800 plate reader (Biotek Instruments, Inc., Winooski, VT,
USA). Plates were incubated for 15 min (IgG) or 20 min (IgG2/3 or IgG1) with OPD substrate before stopping the reaction with 3 M H2 SO4 . Data were analyzed with GraphPad
Prism (Version 8.0 g) using 4-parameter nonlinear regression to determine the titer at which
the curves reach 50% of the top plateau value (50% effective concentration [EC50 ]).
2.8. SARS-CoV-2 Neutralizing Antibody Response
Sera collected from animals were tested for neutralizing capabilities against SARSCoV-2. Briefly, serum samples were heat-inactivated (30 min at 56 ◦ C) and then diluted at
1:10. The diluted sera were serially diluted two-fold in a 96-well plate, and 30 µL of each
serum dilution was mixed with 30 µL of SARS-CoV-2-WA (100 PFU). The serum/virus
mixtures were incubated for 1 h at room temperature; 60 µL of the serum/virus mixtures
were then transferred to Vero E6 cell monolayers in flat-bottom 96-well plates and incubated
for two days at 37 ◦ C. Plates were fixed with 4% PFA and removed from containment.
Plates were blocked and then stained with DAPI at 0.5 µg/mL and the SARS-CoV-2-specific
human antibody CR3022 (produced in-house from plasmids: BEI, Manassas, VA, USA;
NR-53260) conjugated with a Dylight 650 fluorophore at a concentration of 4 µg/mL in
1× DPBS with 5% FBS. Plates were imaged and read on a Cytation5 plate reader (Biotek
Instruments, Inc., Winooski, VT, USA). The convalescent sera were collected from human
volunteers 2–4 weeks post–Washington strain infection in early 2020.
2.9. Rabies Virus Neutralization by RFFIT
Rapid fluorescent focus inhibition tests (RFFITs) were performed as previously described [12]. In brief, mouse neuroblastoma cells (NA) cultured in RPMI media (with
5% FBS) were seeded in 96-well plates and incubated for 48 h. Individual hamster sera
from days 0 and 28 were serially diluted 3-fold, starting at a 1:20 dilution. A prediluted
mixture of Rabies virus (strain CVS-11, previously determined to achieve 90% infection in
confluent NA cells) was added to each serum dilution. The US standard Rabies immune
globulin (World Health Organization standard (WHO STD)) was used at 2 IU/mL starting
dilution. The sera/virus or WHO STD/virus mixture was incubated for 1 h at 34 ◦ C. The
medium was then removed from the NA cell plate, replaced with the sera/virus mix, and
incubated for 2 h at 34 ◦ C. The sera/virus mixture was aspirated and replaced with a fresh
medium post-infection. The plates were then incubated for 22 h (24 hours’ total infection)
at 34 ◦ C. After incubation, cells were fixed with 80% acetone, dried, and stained with
fluorescein isothiocyanate Anti-Rabies N Monoclonal Globulin (Fujirebio, Malvern, PA,
USA) for >4 h. Wells were assessed for percentage infection using a fluorescent microscope.
Fifty percent endpoint titers (EPTs) were calculated using the Reed–Muench method and
converted to international units per milliliter by comparing the sample 50% EPTs to that of
the US standard Rabies immune globulin.
2.10. Tissue Processing
Animals were euthanized on days 3, 7, or 14 post-challenge (p.c.), and lungs and
nasal turbinates were harvested. One lobe of the right lung, the right kidney, and the
right nasal turbinates were placed in prefilled tubes containing 1 mL of viral transport
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medium for viral load analysis. The right lung (one lobe), left nasal turbinates, left kidney,
and spleen were placed in prefilled tubes containing 1mL of TRIzol reagent. The left lung
lobe was perfused with 4% Formaldehyde, placed in a conical tube filled with 6 mL of 4%
Formaldehyde, and put on ice. The lung samples were placed at 4 ◦ C for three days before
processing for histology and staining.
2.11. Viral Load Determination
Tubes containing organs in viral transport medium were homogenized using the BeadBlaster 24R homogenizer, and tissue homogenates were aliquoted and stored at −80 ◦ C.
Tissue homogenates were titrated by TCID50 assay on Vero E6 cell monolayers (ATCC,
Manassas, VA, USA) in 96-well plates to determine viral loads. Plates were incubated for
2 days at 37 ◦ C before being fixed with 4% PFA and removed from containment. Plates were
blocked and then stained with DAPI at 0.5 µg/mL and the SARS-CoV-2-specific human
antibody CR3022 (produced in-house from plasmids: BEI, Manassas, VA, USA; NR-53260)
conjugated with a Dylight 650 fluorophore at a concentration of 4 µg/mL in 1× DPBS with
5% FBS. Plates were imaged and read on a Cytation5 plate reader (Biotek Instruments,
Inc., Winooski, VT). The limit of detection was determined by mixing 1000 PFU/mL,
100 PFU/mL, 50 PFU/mL, and 10 PFU/mL of a known titer SARS-CoV-2 WA strain virus
with lung or tissue homogenates followed by TCID50 assay to calculate the limit of detection.
2.12. Viral RNA Copies by qRT-PCR
Tubes containing organs in TRIzol were homogenized in Bead Ruptor 12 (Omni International, Kennesaw, GA, USA). Then, 100 µL of tissue homogenate was mixed with
900 uL of TRIzol Reagent (Life Technologies, Carlsbad, CA, USA). The RNA extraction protocol for biological fluids using TRIzol Reagent was followed until the phase
separation. The remaining RNA extraction was performed using the PureLink RNA
Mini Kit (Life Technologies, Carlsbad, CA, USA). The quantity and quality (260/280 ratios) of RNA extracted were measured using NanoDrop (Thermo Fisher, Corning, NY,
USA). SARS-CoV-2 envelope gene subgenomic mRNA cDNA was generated from RNA
(BEI Resources, Manassas, VA, USA; NR-52285) by One-Step RT PCR (SuperScript IV,
Thermo Fisher, Corning, NY, USA) with primers SARS-CoV-2 E sgmRNA IVT Fwd (50 GAATTCTAATACGACTCACTATAGGGGATTAAAGGTTTATACCTTCCC-30 ) and SARSCoV-2 E sgmRNA IVT Rev (50 -GCTAGCTTAGACCAGAAGATCAGGAACTC-30 ). The
SARS-CoV-2 E sgmRNA standards were generated by in vitro transcription of the generated
SARS-CoV-2 E sgmRNA cDNA using the MegaScript T7 Transcription kit (Thermo Fisher,
Corning, NY, USA), followed by the MEGAclear Transcription Clean-Up Kit. Aliquots of
2 × 1010 copies/µL were frozen at −20 ◦ C. Five microliters of RNA per sample was run in
triplicate using the primers: SARS-CoV-2 E sgmRNA Fwd (50 -CGATCTCTTGTAGATCTGTTC
TC-30 ), SARS-CoV-2 E sgmRNA Rev (50 -ATATTGCAGCAGTACGCACACA-30 ), and probeFAM (50 -ACACTAGCCATCCTTACTGCGCTTCG-30 ).
2.13. Cytokine qPCR
Duplicates of each lung RNA sample were assessed for the presence of several cytokines in a multiplex format. Three 5-Plex assays were generated: (1) γ-actin, IFN-γ,
CCL17, CCL3, and CCL5, (2) γ-actin, CXCL10, IFN-α, IL10, and IL12 p40, and (3) γ-actin,
IL17, IL21, and IL4. One 4-Plex assay was generated to assess γ-actin, IL-6, TGF-β1, and
TNF-α. The mRNA assay primer and probe sequences are listed in Table S2. The fold gene
expression was calculated by 2-∆∆Ct by calculating the ∆Ct for vaccinated, control, and
untreated hamster lungs. Of note, CXCL10 was not detectable in any animal.
2.14. Histology
Hamster lungs were harvested in 4% PFA and stored at 4 ◦ C. The tissue was dehydrated, fixed, and infiltrated with paraffin on the Leica Polaris 2 tissue processor. The
infiltrated tissue was then embedded and sectioned at 5 microns. Antigen retrieval was
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performed on the Roche Ventana Discovery ULTRA staining platform using Discovery CC1
(Roche, Indianapolis, IN, USA; Cat#950-500) for a total application time of 64 min. The primary antibody, human Anti-SARS-CoV-2 Nucleocapsid monoclonal (E16C) (Thermo Fisher,
Corning, NY, USA; MA1-7403, 0.1 mg/mL), was incubated at a 1:100 dilution, at room
temperature, for 45 min. Secondary immunostaining used a horseradish peroxidase (HRP)
multimer cocktail (Roche, Indianapolis, IN, USA; Cat#760-500), and immune complexes
were visualized using the ultraView Universal DAB (diaminobenzidine tetrahydrochloride)
Detection Kit (Roche, Indianapolis, IN, USA; Cat#760-500). Slides were then washed with a
Tris-based reaction buffer (Roche, Indianapolis, IN, USA; Cat#950-300) and counter-stained
with Hematoxylin II (Roche, Indianapolis, IN, USA; Cat #790-2208) for 4 min. Scoring was
performed as shown in Table S2.
2.15. Antibody-Dependent Effector Functions
The assay was performed in 96-well, flat, white-bottom plates (Thermo Fisher, Corning,
NY, USA) preseeded with 30,000 Vero CCL81 cells and infected after 24 h with Measles
vaccine (Edmonston B strain) vector expressing full-length SARS-CoV-2 spike at an MOI
of 0.5. After 60 h, the medium was removed, and 25 µL of assay buffer (RPMI 1640 with
4% low-IgG FBS) was added to each well. Sera were pooled from each group and heatinactivated for analysis. Then, 25 µL sera at a starting dilution of 1:30 was serially diluted
3-fold in assay buffer (in duplicates). The sera were then incubated with the infected
cells for 30 min at 37 ◦ C. Post-challenge (day 15 post-challenge) hamster sera from the
unvaccinated challenged group were used as a control. Genetically modified Jurkat cells
expressing mouse FcγR IV with a luciferase reporter gene under the transcriptional control
of nuclear-factor-activated T cell (NFAT) promoter were added at 1.5 × 105 cells in 25 µL per
well, which is approximately a 5:1 ratio of effector cells (Promega, Madison, WI, USA) to
target cells. Cells were then incubated for another 6 h at 37 ◦ C. After the incubation, 75 µL
of Bio-Glo Luciferase assay reagent was added, and luminescence was quantified using a
microplate reader. Fold induction was measured in relative light units and calculated by
subtracting the background signal from wells without effector cells and dividing values
for wells with antibodies by values for those with no antibody added. Specifically, fold
induction was calculated: (RLUinduced − RLUbackground )/(RLUuninduced − RLUbackground ).
The mean values and standard errors of the means (SEM) were reported, and a nonlinear
regression curve was generated using GraphPad Prism 9.
2.16. Statistical Analysis
An unpaired two-tailed nonparametric t-test (Mann–Whitney) was performed on
log-transformed data for each time point for the ELISA, virus-neutralizing antibody, viral
load, and qPCR assays. An unpaired nonparametric two-tailed Mann–Whitney test was
performed on percentage weights for each time point for the weight curves. p values
are reported.
3. Results
3.1. Immunogenicity of a Single Dose of CORAVAX in Syrian Hamsters
We previously described the Rabies virus-vectored SARS-CoV-2 vaccine CORAVAX™ [11].
Utilizing the SAD-B19 Rabies vaccine strain, the S1 subunit of the SARS-CoV-2 spike protein
(S) was incorporated into RABV virions. To promote the incorporation of the S1 domain,
we constructed a gene encoding a fusion protein between 682aa of the N-terminus of
SARS-CoV-2 S fused to a C-terminal domain of RABV glycoprotein (G) [11]. Two doses
of inactivated CORAVAX were efficacious in hamsters and mice and induced high virusneutralizing antibodies (VNA) [11,13].
Here, we evaluated the effectiveness of a single dose of CORAVAX in the Syrian
hamster model. To this end, we vaccinated two groups of fifteen golden Syrian hamsters
intramuscularly (i.m.) with either 10 µg of inactivated CORAVAX or the control vaccine
FILORAB1 (Rabies-vectored Ebola vaccine) [14] adjuvanted with a squalene-based adjuvant
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Here, we evaluated the effectiveness of a single dose of CORAVAX in the Syrian
hamster model. To this end, we vaccinated two groups of fifteen golden Syrian hamsters
8 of 21
intramuscularly (i.m.) with either 10 μg of inactivated CORAVAX or the control vaccine
FILORAB1 (Rabies-vectored Ebola vaccine) [14] adjuvanted with a squalene-based adjuvant
(SEPIVAC
Seppic).
The animals
were inoculated
day bled
0 andonbled
0,
(SEPIVAC
SWE,SWE,
Seppic).
The animals
were inoculated
on dayon
0 and
dayson0,days
14, and
14,
and
28
(Figure
1).
On
day
39,
vaccinated
and
control
hamsters
were
challenged
in28 (Figure 1). On day 39, vaccinated and control hamsters were challenged intranasally
4 PFU of the SARS-CoV-2 isolate USA_WA1/2020. Five animals
4 PFU
tranasally
with
a dose
ofof10the
with a dose
of 10
SARS-CoV-2 isolate USA_WA1/2020. Five animals from each
from
each
group
were
necropsied
days143,post-challenge.
7, and 14 post-challenge.
group were necropsied on days 3,on
7, and
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Animals were necropsied on days 42 (day 3 p.c.), 46 (day 7 p.c.), and 53 (day 14 p.c.). Created with
BioRender.com.
BioRender.com.

To analyze the immunogenicity of the CORAVAX vaccine, the sera from both groups
To analyze the immunogenicity of the CORAVAX vaccine, the sera from both groups
of hamsters were assayed for SARS-CoV-2-specific antibody responses by ELISA specific
of hamsters were assayed for SARS-CoV-2-specific antibody responses by ELISA specific
for SARS-CoV-2 S1 as well as the receptor-binding site (RBD) (Figure 2). We observed
for SARS-CoV-2 S1 as well as the receptor-binding site (RBD) (Figure 2). We observed
high SARS-CoV-2 S1 and RBD-specific IgG responses in the CORAVAX group as early
high
SARS-CoV-2
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IgG responses
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groupuntil
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as day
14 post-vaccination.
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28
day
14 post-vaccination.
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28 (Figure
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thatthe
a single
inoculation may
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level
of protection.
analyzed
sera post-challenge
(p.c.).
Of note,
on day
3 p.c.
(day 42), we observed
S1 IgG and IgG2/3 and RBD IgG responses only in the CORAVAX-vaccinated animals,
except one animal in the control group, which had a low level of RBD IgG responses
(Figure 2A–C). On days 7 and 14 p.c. (days 46 and 53), we observed significantly increased
S1 IgG responses in the CORAVAX group, which were approximately 64-fold (day 7) and
9-fold (day 14) higher than the responses seen in the control group (Figure 2A). Moreover,
the CORAVAX-vaccinated animals induced a strong Th1-biased immune response at time
points post-challenge, a feature previously shown to be beneficial in combatting SARS-CoV2 infection [15]. In contrast, control animals immunized with FILORAB1 induced either no
S1 IgG2/3 responses or low levels in the case of two animals only on day 14 p.c. (day 53)
(Figure 2C). As previously reported, we detected no significant differences in immune
responses against the RBD IgG responses on days 7 and 14 p.c. for all groups (Figure 2B).
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On days 7 and 14 p.c. (days 46 and 53), we observed significantly increased
against
SARS-CoV-2.
S1 IgG responses in the CORAVAX group, which were approximately 64-fold (day 7) and
9-fold (day 14) higher than the responses seen in the control group (Figure 2A). Moreover,
the CORAVAX-vaccinated animals induced a strong Th1-biased immune response at time
points post-challenge, a feature previously shown to be beneficial in combatting SARSCoV-2 infection [15]. In contrast, control animals immunized with FILORAB1 induced either no S1 IgG2/3 responses or low levels in the case of two animals only on day 14 p.c.
(day 53) (Figure 2C). As previously reported, we detected no significant differences in
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immune responses against the RBD IgG responses on days 7 and 14 p.c. for all groups
(Figure 2B).
While the ELISA data are helpful for following immune responses over time and analyzing the quality of such responses, we tested the potency of the sera to neutralize SARSCoV-2 using a virus neutralization antibody (VNA) assay. Figure 3 shows VNA10titers
of 21
against SARS-CoV-2.
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As shown above, CORAVAX is immunogenic; therefore, the hamsters were chalAs shown above, CORAVAX is immunogenic; therefore, the hamsters were challenged intranasally on day 39 with 1044 PFU of SARS-CoV-2 isolate USA_WA1/2020 and
lenged intranasally on day 39 with 10 PFU of SARS-CoV-2 isolate USA_WA1/2020 and
were monitored for up to 14 days. The CORAVAX-vaccinated animals showed significantly less weight loss than the FILORAB1 controls, which lost more than 6% weight
(Figure 4). On days 3, 7, and 14 p.c., five hamsters in each study group were humanely
euthanized, and lungs, nasal turbinates, spleen, and kidneys were harvested. The viral
loads were determined by assaying RNA for viral copies of replicating virus for subgenomic
(sg) mRNA by RT-qPCR assay (Figure 5A,B) and infectious viral loads by TCID50 assay
(Figure 5C,D). Significantly lower sgmRNA and infectious viral loads were detected in the
lungs of the CORAVAX-vaccinated animals on day 3 post-challenge (Figure 5A,C). On day
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thanized, and lungs, nasal turbinates, spleen, and kidneys were harvested. The viral loads
were determined by assaying RNA for viral copies of replicating virus for subgenomic
(sg) mRNA by RT-qPCR assay (Figure 5A,B) and infectious viral loads by TCID50 assay
(Figure 5C,D). Significantly lower sgmRNA and infectious viral loads were detected in
11 of 21
the lungs of the CORAVAX-vaccinated animals on day 3 post-challenge (Figure 5A,C).
On day 7 post-challenge, significantly lower sgmRNA was detected in the lungs of the
CORAVAX group, but no detectable infectious virus was seen in either the vaccine or
control
groups (Figure
5A,C). Onlower
day 14
post-challenge,
there was
nolungs
detectable
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significantly
sgmRNA
was detected
in the
of theinfectious
CORAVAX
SARS-CoV-2
in
either
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similarly
low
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both
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(Figure
5A,C).
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only
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on
(Figure 5A,C). On day 14 post-challenge, there was no detectable infectious SARS-CoV-2
day
p.c., with
noalthough
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two groups
5B,D).
in 3either
group,
similarly
lowbetween
levels ofthe
sgmRNA
were (Figure
detected
in both groups
(Figure 5A,C). In the nasal turbinates, we only detected infectious virus on day 3 p.c., with
no significant differences between the two groups (Figure 5B,D).
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group (5 hamsters each euthanized on days 3, 7, and 14 p.c.) and n = 15 for CORAVAX group
hamsters each euthanized on days 3, 7, and 14 p.c.). Body weight p value determined by Wilcoxon
(5 hamsters each euthanized on days 3, 7, and 14 p.c.). Body weight p value determined by Wilcoxon
test; p > 0.123 (ns), p < 0.033 (*), p < 0.002 (**), p < 0.001 (***).
test; p > 0.123 (ns), p < 0.033 (*), p < 0.002 (**), p < 0.001 (***).

3.4. A Single Dose of CORAVAX Can Significantly Reduce Lung Pathology in Hamsters
Lung sections were collected from control and vaccinated animals on days 3, 7, and
14 p.c. and processed for histology (Figures 6–8). The images and description of the
histological changes identified in this study are provided in Supplementary Figure S2.
Sections were scored in a blinded manner (scoring criteria, Supplementary Table S1). On
day 3 p.c., the control FILORAB1 specimens showed severe, patchy inflammation involving
more than 50% of the examined lung with severe involvement of the airways (bronchitis/bronchiolitis), extending into the alveolar septa (pneumonitis) with alveolar edema
and hemorrhage (Figures 6–8). We also noted severe vasculitis. The immunohistochemical
stain for the SARS-CoV-2 nucleoprotein antigen showed extensive multifocal positive cells
involving bronchial epithelium, alveolar epithelium, and macrophages. In contrast, on
day 3 p.c., the CORAVAX-vaccinated specimens showed only mild to moderate patchy
inflammation involving less than 50% of the examined lung with mild to moderate airway inflammation, mild alveolar wall infiltration, congestion, and interstitial edema. We
also noted focal mild vasculitis. The immunohistochemical stain for the SARS-CoV-2
nucleoprotein antigen showed only multifocal positive bronchial cells.
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On day 14 p.c., the control FILORAB1 specimens showed improvement, with inflammation involving less than 30% of the lung with mild to moderate airway inflammation,
mild to moderate alveolar congestion, edema, and mild vasculitis (Figures 6–8). The immunohistochemical stain for the SARS-CoV-2 nucleoprotein antigen showed no definite
positive cells. On day 14 p.c., the CORAVAX-vaccinated group showed no significant airway inflammation, only mild alveolar congestion and edema, and no significant vasculitis.
The immunohistochemical stain for the SARS-CoV-2 nucleoprotein antigen showed no
definite positive cells.
3.5. A Single Dose of CORAVAX Can Significantly Prevent SARS-CoV-2-Induced Cytokine Storm
in the Lungs
Uncontrolled induction of inflammation is one of the hallmarks of pathology after
infection with SARS-CoV-2 [16]. Therefore, the lungs of the vaccinated and control animals
were assayed for cytokine (IFN-γ, IFN-α, IL-10, IL-6, IL-4, IL-2, IL-21, IL-17, TGF-β1, and
TNF-α) and chemokine (CCL5 and CCL3) expression by qRT-PCR (primer and probe
sequences, Supplementary Table S2), normalized to γ-actin and expressed as fold changes
over the average expression of three uninfected, unchallenged hamsters. On days 3 and/or
7 post-challenge, we observed significantly higher levels of inflammatory cytokines IFN-γ,
IFN-α, IL-10, and IL-6 in the control groups than were detected in CORAVAX-immunized
animals (Figure 9). CCL5 and IL-4 were only detectable in the control groups, suggesting
a more substantial Th2 bias in the control group, as seen in the isotype-specific ELISA
presented above (Figure 2C). On day 7 p.c., there was a significant upregulation of CCL3,
IL-2, IL-21, and TGF-b1 in the CORAVAX-vaccinated animals, which may have contributed
to dampening the inflammation and allowing for viral clearance, as observed in the lung
histology (Figure 6C,D and Figure 8C,D). We saw no significant difference in the IL17 and IL-12 p40 expression between the two groups after the challenge (Figure 9 and
Supplementary Figure S3. Of note, CXCL10 was not detectable in any animal.
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On day 7 p.c., the control FILORAB1 specimens still showed significant inflammation
involving around 50% of the examined lung (Figures 6–8). The disease is multifocal, nodular, and bronchiolocentric with moderate to severe involvement of the airways and alveolar wall infiltration, edema, congestion, and focal hemorrhage. We also noted mild to
moderate vasculitis. The immunohistochemical stain for the SARS-CoV-2 nucleoprotein
antigen showed multifocal positive cells involving both bronchial epithelia and alveolar
epithelia but to a much lesser extent than those observed on day 3 p.c. On day 7, the CORAVAX-vaccinated group showed significant improvement, with only mild airway in-
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quantified by real-time RT-PCR. γ-Actin mRNA was used as an internal control. Data are shown
as fold change in gene expression compared to normal animals (unimmunized and unchallenged)
after normalization. Data were analyzed using Mann–Whitney test for each time point (* p < 0.05;
** p < 0.01; *** p < 0.001).

3.6. A Single Dose of CORAVAX Induces Antibodies with Antibody-Dependent Cellular
Cytotoxicity Activity
While we previously found high VNA titers in animals immunized with CORAVAX,
we wanted to test if CORAVAX also induced non-neutralizing antibody functions. To understand the potential mechanism of S1 antibody-mediated protection, we tested pre-challenge
hamster sera (day 28) from vaccinated and controlled animals for antibody-dependent
cellular cytotoxicity (ADCC) activity using a recombinant measles virus expressing SARSCoV-2 S in Vero-CCL81 cells. These reporter cells showed ADCC activation in the ADCC
Reporter Bioassay, where the Fc portion of the antibody binds to the FcγRIIIa (mouse) of
the effector cells (Jurkat) and results in a quantifiable luminescence signal from the NFAT
(nuclear factor of activated T-cells) pathway. We observed the highest ADCC activity in the
CORAVAX serum. In contrast, we observed no ADCC activity in post-challenge hamster
sera (15 days p.c.) or the control FILORAB1 groups (Figure 10), suggesting that CORAVAX
induced antibodies with neutralizing and non-neutralizing functions.
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development of modified or new vaccines with broader coverage. While studies have verified
waning immunity after six months for the mRNA vaccines (Pfizer and Moderna) and
two months after the J&J vaccine, it is still debated whether a prior infection can provide
long-term protection [17,18]. Although protection from reinfection decreases with time
in previously infected individuals, it is higher than in those who received two doses of
the Pfizer vaccine [19]. Maintaining public health measures to curb transmission as the
COVID-19 pandemic continues is critical for preventing morbidity and mortality. Modifying guidelines as per immunity status to improve vaccine coverage may be required.
Studies have shown that a single dose of the vaccine in previously infected individuals is as
protective as, if not better than, two doses of the mRNA or a single dose of the AstraZeneca
vaccine [20–22].
Most of the current WHO-approved vaccines (mRNA-1273, BNT162b2, and Ad26.COV2.S)
utilize the prefusion-stabilized spike protein as the antigen [6]. For the mRNA vaccines,
although the antigen is similar, they differ in their mRNA content (100 µg for mRNA-1273
vs. 30 µg for BNT162b2), the dosing interval between prime and boost vaccines (4 weeks
for mRNA-1273 vs. three weeks for BNT162b2), and the lipid composition of the nanopar-
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ticles used for packaging the mRNA content [2]. Initial studies demonstrated similar
efficacy for both mRNA vaccines. Among the WHO-approved replication-incompetent
adenoviral vaccines, AstraZeneca’s ChAdOx1 nCoV-19 vaccine (AZD1222) and Jansen’s
Ad26.COV2, AZD1222 expresses the full-length spike, while Ad26.COV2.S expresses a
prefusion-stabilized spike protein. Both vaccines are efficacious (~66–76%) but to a lower
extent than the mRNA vaccines [23]. Large-scale human adenoviral COVID-19 vaccinations appear to be associated with rare cases of vaccine-induced immune thrombocytopenia (VITT) that may be due to the interaction of the viral vector with platelet factor
4 (PF4) [24–30]. Recently, WHO gave emergency use approval to an adjuvanted recombinant nanoparticle vaccine from NOVAVAX, NVX-CoV2373, with an efficacy of 89.7% in
phase 3 trials [31–33].
The emergence of variants in the presence of waning vaccine immunity has raised
concerns worldwide. A major current issue is that all vaccines express the ancestral SARSCoV-2 spike, whereas the currently circulating variants, including Delta and Omicron, have
significant mutations in the spike-encoding region, rendering the vaccine less effective and
giving rise to mutants. Generating and testing new variant vaccines may be required to
control the spread of SARS-CoV-2. Single-dose variant vaccines that can induce long-term
immunity may help to improve vaccine coverage and reduce reinfection rates. Testing vaccines in previously infected animals may become critical as infection rates rise worldwide.
In addition, developing standardized assays to determine the virus-neutralizing titer (VNT)
thresholds essential for protection may improve vaccine quality [34].
Here, we report the immunogenicity, efficacy, reduced lung inflammation, and potential mechanism of our single-dose S1-based COVID-19 vaccine, CORAVAX, in hamsters.
The antigen used is a chimeric protein that contains the S1 domain (1-682aa) fused to the
C-terminus of RABV-G for tethering to the Rabies virus virion. We previously analyzed the
correct folding of our chimeric S1 in CORAVAX by verifying its binding to the hACE2 protein [11]. An S1-based vaccine, when folded correctly, might serve as a good immunogen,
as it ensures immune responses against the important neutralizing epitopes identified in
human convalescent patients that recognize RBD, NTD S1, and the quaternary epitope that
bridges the two RBDs [35].
Our previous study showed that two doses of CORAVAX adjuvanted with MPLAAddavax, a TRL4 agonist, induced high levels of neutralizing antibodies, generated a
strong Th1-biased immune response (indicated by high S1 IgG2/3 responses), and were
efficacious in hamsters with viral clearance in the nasal turbinates [13]. In human patients
with mild/recovered COVID-19, a Th1-biased immune response is beneficial for protection
against disease [36]. The current study used SEPIVAC SWE (developed by VFI and Seppic)
adjuvant, a squalene-in-water emulsion, similar to Addavax (Invivogen) tested in our
previous study. We observed a significant increase in antibody and VNTs from day 14 to
day 28 with a single dose of adjuvanted inactivated CORAVAX, suggesting antigen stability.
Of note, CORAVAX induced high 100% VNT titers. As previously published, CORAVAX
induced a strong Th1-biased immune response, which helped significantly reduce inflammation and viral loads in the lungs. The controls induced a stronger inflammatory cytokine
and chemokine response in the lungs on day 3 and day 7 post-challenge than the vaccinated
animals, in addition to the Th2 cytokines only being induced in the control group. Sera
from CORAVAX-vaccinated hamsters demonstrate antibody-dependent cytotoxic activity,
suggesting a dual function of the antibodies. Therefore, we can conclude that a single dose
of CORAVAX is efficacious and prevents weight loss and the cytokine storm seen in the
control lungs.
The histopathologic tissue examination on days 3 and 7 p.c. showed that the CORAVAXvaccinated animals had significantly reduced inflammation, as indicated by the accumulation of inflammatory cells compared to the controls. CORAVAX-vaccinated animals always
had significantly lower average pathology lung scores, indicating excellent protection from
lung disease. A significantly higher amount of antigen was detected in the lungs of the
controls than in the CORAVAX-vaccinated animals on days 3 and 7 p.c. By day 14 p.c., the
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inflammation was completely cleared in the vaccinated animals and significantly reduced
in the control unvaccinated group, and the antigen was absent in the lungs of both groups,
which is a common feature of the hamster model. The hamster model is well established
for SARS-CoV-2, as it mimics the human lung pathology seen in COVID-19 patients [16].
This study concludes that SARS-CoV-2-challenged CORAVAX-vaccinated animals never
developed the severe inflammation associated with the disease (compared with the control
animals). We also observed a rapid decline and early elimination of the SARS-CoV-2 nucleoprotein antigen in the vaccinated animals (compared with the unvaccinated counterparts).
These findings are a strong indication of protection of the lungs by the CORAVAX vaccine.
This study is the first to show the efficacy of a single-dose RABV-vectored COVID-19
vaccine, CORAVAX, in the Syrian hamster model of severe disease. The Rabies vaccine
vector has significant advantages, including (1) an excellent safety profile, (2) approved administration to pregnant women, children, and the immunocompromised, (3) the induction
of lifelong immunity, (4) amenable to boosting several times, and (5) less reactogenicity [37].
This study showed significant protection with a single dose of CORAVAX, yet it is evident
that two doses are required for complete viral clearance from the nasal turbinates. Studies
evaluating the longevity of immune responses after a single dose and the boosting potential of CORAVAX in previously infected hamsters are yet to be assessed. Production of
CORAVAX is facile, as it would follow the existing RABV vaccine manufacturing facilities
and technologies. To further evaluate CORAVAX, a phase I human clinical trial is being
conducted in India by Bharat Biotech International Ltd., with plans for a follow-up phase I
study in the US [38]. To summarize, CORAVAX is a promising COVID-19 vaccine candidate
with an excellent safety profile and proven efficacy in several animal studies.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/v14061126/s1, Figure S1: Rabies virus neutralizing antibodies;
Figure S2: High magnification images showing different pathologic findings observed; Figure S3: IL12p40 mRNA levels by qPCR; Table S1: Semi-quantitative histopathological scoring criteria; Table S2:
List of cytokine/chemokine qPCR primers and probes sequences [39].
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